References

Aiken, A.M., Rehman, A.M., de Kraker, M.E.A., Madrid, L., Kebede, M., Labi, A.-K., Obeng-Nkrumah, N., Nyamwaya, B., Kagucia, E., Cocker, D., Kawaza, K., Lester, R., Iregbu, K.C., Medugu, N., Nwajiobi-Princewill, P.I., Dramowski, A., Sonda, T., Hemed, A., Fwoloshi, S., Ojok, D., Scott, J.A.G. and Whitelaw, A. (2023) ‘Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study’, The Lancet: Infectious Diseases, 23(11), pp. 1280–90, November [online]. Available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00233-5/fulltext (accessed 9 Septeember 2025).

Altevogt, B.M., Taylor, P., Akwar, H.T., Graham, D.W., Ogilvie, L.A., Duffy, E. and Essack, S.Y. (2025) ‘A One Health framework for global and local stewardship across the antimicrobial lifecycle’, Communications Medicine, 5, article number 414, 7 October [online]. Available at https://www.nature.com/articles/s43856-025-01090-4 (accessed 17 October 2025).

AMASS, https://amass.website/infobox.aspx?pageID=101 (accessed 9 September 2025).

AMR (for R), https://amr-for-r.org/ (accessed 9 September 2025).

Antimicrobial Resistance Collaborators (AMRC) (2022) ‘Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis’, The Lancet, 399(10325), pp. 629–55, 12 February [online]. Available at https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext (accessed 9 September 2025).

Bertram, M.Y., Lauer, J.A., De Joncheere, K., Edejer, T., Hutubessy, R., Kienya, M.-P. and Hilla, S.R. (2016) ‘Cost–effectiveness thresholds: pros and cons’, Bulletin of the World Health Organization, 94(12), pp. 925–30 [online]. Available at https://doi.org/10.2471/blt.15.164418 (accessed 10 September 2025).

de Kraker, M.E.A., Stewardson, A.J. and Harbarth, S. (2016) ‘Will 10 million people die a year due to antimicrobial resistance by 2050?’, PLOS Medicine, 13(11), p. e1002184 [online]. Available at https://doi.org/10.1371/journal.pmed.1002184 (accessed 10 September 2025).

De Silva, S. and Higgins, A.M. (2023) ‘Clinimetrics: the quality adjusted life year’, Journal of Physiotherapy, 69(1), pp. 58–9 [online]. Available at https://doi.org/10.1016/j.jphys.2022.06.008 (accessed 10 September 2025).

Elliott, T.M., Harris, P.N., Roberts, L.W., Doidge, M., Hurst, T., Hajkowicz, K., Forde, B., Paterson, D.L. and Gordon, L.G. (2021) ‘Cost-effectiveness analysis of whole-genome sequencing during an outbreak of carbapenem-resistant Acinetobacter baumannii’, Antimicrobial Stewardship & Healthcare Epidemiology, 1(1), e62, 13 December [online]. Available at https://www.cambridge.org/core/journals/antimicrobial-stewardship-and-healthcare-epidemiology/article/costeffectiveness-analysis-of-wholegenome-sequencing-during-an-outbreak-of-carbapenemresistant-acinetobacter-baumannii/D7FBAD9D70CEB555A858FE1B302C30B1 (accessed 7 October 2025).

Feikin, D.R., Scott, J.A. and Gessner, B.D. (2014) ‘Use of vaccines as probes to define disease burden’, The Lancet, 383(9930), pp. 1762–70; erratum in The Lancet, 383(9935), p. 2126 [online]. Available at https://doi.org/10.1016/s0140-6736(13)61682-7 (accessed 7 October 2025).

Gebretekle, G.B., Mariam, D.H., Mac, S., Abebe, W., Alemayehu, T., Degu, W.A., Libman, M., Yansouni, C.P., Fenta, T.G., Semret, M. and Sander, B. (2021) ‘Cost–utility analysis of antimicrobial stewardship programme at a tertiary teaching hospital in Ethiopia’, BMJ Open, 11(12), e047515, 17 December [online]. Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC8685939/ (accessed 10 September 2025).

Global Burden of Disease Study 2021 (GBD) (2021) ‘Disability weights’, GHDx [online]. Available at https://ghdx.healthdata.org/record/ihme-data/gbd-2021-disability-weights (accessed 1 June 2025).

Global Laboratory eTools (n.d.) ‘SEDRI LIMS’ [online]. Available at https://www.lab-etools.org/etool/sedri-lims/ (accessed 9 September 2025).

Institute for Health Metrics and Evaluation (IHME) (n.d.) ‘Antimicrobial resistance (AMR)’ [online]. Available at https://www.healthdata.org/research-analysis/health-topics/antimicrobial-resistance-amr-our-approach (accessed 9 September 2025).

Institute for Health Metrics and Evaluation (IHME)/University of Oxford (n.d.) ‘MICROBE’ [online]. Available at https://vizhub.healthdata.org/microbe/ (accessed 9 September 2025).

Kazibwe, J., Gheorghe, A., Wilson, D., Ruiz, F., Chalkidou, K. and Chi, Y.-L. (2022) ‘The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review’, Value in Health, 25(3), pp. 385–9 [online]. Available at https://doi.org/10.1016/j.jval.2021.08.014 (accessed 10 September 2025).

Martins, S.B., Afonso, J.S., Fastl, C., Huntington, B. and Rushton, J. (2024) ‘The burden of antimicrobial resistance in livestock: a framework to estimate its impact within the Global Burden of Animal Diseases programme’, One Health, 19, pp. 100917–100917 [online]. Available at https://doi.org/10.1016/j.onehlt.2024.100917 (accessed 10 September 2025).

MirkovonHein [YouTube user] (2024) ‘Direct vs. indirect cost in HEOR’, YouTube, 10 November [online]. Available at https://www.youtube.com/shorts/GRj0TnntQLI (accessed 9 September 2025).

Ochalek, J., Lomas, J. and Claxton, K. (2018) ‘Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data’, BMJ Global Health, 3(6) [online]. Available at https://doi.org/doi:10.1136/bmjgh-2018-000964 (accessed 10 September 2025).

Poudel, A.N., Zhu, S., Cooper, N., Little, P., Tarrant, C., Hickman, M. and Yao, G. (2023) ‘The economic burden of antibiotic resistance: a systematic review and meta-analysis’, PLOS One, 8 May [online]. Available at https://doi.org/10.1371/journal.pone.0285170 (accessed 10 September 2025).

Review on Antimicrobial Resistance, https://amr-review.org/ (accessed 1 June 2025).

Rodríguez-Baño, J., López-Prieto, M.D., Portillo, M.M., Retamar, P., Natera, C., Nuño, E., Herrero, M., del Arco, A., Muñoz, A., Téllez, F., Torres-Tortosa, M., Martín-Aspas, A., Arroyo, A., Ruiz, A., Moya,. R., Corzo, J.E., León, L., Pérez-López, J.A. and SAEI/SAMPAC Bacteraemia Group (2010) ‘Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals’, Clinical Microbiology and Infection, 16(9), pp. 1408–13 [online]. Available at https://pubmed.ncbi.nlm.nih.gov/19845694/ (accessed 8 September 2025).

Salinas-Escudero, G., De la Rosa-Zamboni, D., Carrillo-Vega, M.F., Gamiño-Arroyo, A.E., Toledano-Toledano, F., Ortega-Riosvelasco, F., Granados-García, V., Villa-Guillén, M. and Garduño-Espinosa, J. (2023) ‘Cost-effectiveness analysis of a hand hygiene monitoring system in a tertiary pediatric hospital in Mexico’, Frontiers in Public Health, 11:1117680 [online]. Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC10034395/ (accessed 9 September 2025).

Shrestha, P., Cooper, B.S., Coast, J., Oppong, R., Thuy, N.D.T., Phodha, T., Celhay, O., Guerin, P.J., Wertheim, H. and Lubell, Y. (2018) ‘Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use’, Antimicrobial Resistance & Infection Control, 7 [online]. Available at https://doi.org/10.1186/s13756-018-0384-3 (accessed 10 September 2025).

Torgerson, P.R., Rüegg, S., Devleesschauwer, B., Abela-Ridder, B., Havelaar, A.H., Shaw, A.P.M., Rushton, J. and Speybroeck, N. (2018) ‘zDALY: An adjusted indicator to estimate the burden of zoonotic diseases’, One Health, 5, pp. 40–45 [online]. Available at https://doi.org/10.1016/j.onehlt.2017.11.003 (accessed 10 September 2025).

Turner, P., Andrew Fox-Lewis, A., Shrestha, P., Dance, D.A.B., Wangrangsimakul, T., Cusack, T.-P., Ling, C.L., Hopkins, J., Roberts, T., Limmathurotsakul, D., Cooper, B.S., Dunachie, S., Moore, C.E., Dolecek, C., van Doorn, H.R., Guerin, P.J., Day, N.P.J. and Ashley, E.A. (2019) ‘Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data’, BMC Medicine, 17(1), p. 70 [online]. Available at https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1301-1 (accessed 7 October 2025).

Turner, H.C., Archer, R.A., Downey, L.E., Isaranuwatchai, W., Chalkidou, K., Jit, M. and Teerawattananon, Y. (2021) ‘An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations’, Frontiers in Public Health, 9, 25 August [online]. Available at https://doi.org/10.3389/fpubh.2021.722927 (accessed 10 September 2025).

Turner, H.C., Sandmann, F.G., Downey, L.E., Orangi, S., Teerawattananon, Y., Vassall, A. and Jit, M. (2023) ‘What are economic costs and when should they be used in health economic studies?’, Cost Effectiveness & Resource Allocation, 21(1), pp. 1–11 [online]. Available at https://doi.org/10.1186/s12962-023-00436-w (accessed 10 September 2025).

United Nations (2016) ‘Political declaration of the high-level meeting of the General Assembly on antimicrobial resistance’, 71st session, agenda item 127, 22 September. New York, NY: UN [online]. Available at https://digitallibrary.un.org/record/842813?ln=en&v=pdf (accessed 10 September 2025).

WHONET, https://whonet.org/ (accessed 9 September 2025).

Woods, B., Revill, P, Sculpher, M. and Claxton, K. (2016) ‘Country-level cost-effectiveness thresholds: Initial estimates and the need for further research’, Value in Health, 19(8), pp. 929–35 [online]. Available at https://doi.org/10.1016/j.jval.2016.02.017 (accessed 10 September 2025).

World Bank Group (2024) ‘Antimicrobial resistance (AMR)’, brief, 2 October [online]. Available at https://www.worldbank.org/en/topic/health/brief/antimicrobial-resistance-amr (accessed 1 June 2025).

World Health Organization (WHO) (2017) Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2016–17. Geneva: WHO [online]. Available at https://cdn.who.int/media/docs/default-source/searo/amr/global-antimicrobial-resistance-surveillance-system-(glass)-report-early-implementation-2016-2017.pdf (accessed 8 September 2025).

World Health Organization (WHO) (n.d. 1) ‘Countries/areas by WHO region’ [online]. Available at https://ourworldindata.org/grapher/who-regions#:~:text=World%20Health%20Organization%20%E2%80%93%20Countries/areas,20region%2520%2D%252012bfe12.pdf (accessed 9 September 2025).

World Health Organization (WHO) (n.d. 2) ‘GLASS dashboard’ [online]. Available at https://worldhealthorg.shinyapps.io/glass-dashboard/_w_a891c93dd3ad4f328ca95650d995da3d/#!/amr (accessed 9 September 2025).

World Health Organization (WHO) (n.d. 3) ‘Global Antimicrobial Resistance and Use Surveillance System (GLASS)’ [online]. Available at https://www.who.int/initiatives/glass (accessed 9 September 2025).

World Health Organization (WHO) (n.d. 4) ‘Library of AMR national action plans’ [online]. Available at https://www.who.int/teams/surveillance-prevention-control-AMR/national-action-plan-monitoring-evaluation/library-of-national-action-plans (accessed 8 September 2025).

Further reading

Buckley, G.J. and Palmer, G.H. (eds) (2022) ‘The health and economic burden of resistance’, Chapter 3 in Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine. Washington, DC: National Academies Press [online]. Available at https://www.ncbi.nlm.nih.gov/books/NBK577288/ (accessed 10 September 2025).

Love-Koh, J., Walker, S.M., Kataika, E., Sibandze, S., Arnold, M., Ochalek, J., Griffin, S., Revill, P. and Sculpher, M. (2019) Economic Analysis for Health Benefits Package Design, CHE Research Paper 165. York: Centre for Health Economics, University of York [online]. Available at https://eprints.whiterose.ac.uk/id/eprint/147199/1/CHERP165_economic_analysis_HBP.pdf (accessed 10 September 2025).

Mendelson, M., Lewnard, J.A., Sharland, M., Cook, A., Pouwels, K.B., Alimi, Y., Mpundu, M., Wesangula, E., Weese, J.S., Røttingen, J.A. and Laxminarayan, R. (2024) ‘Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach’, The Lancet, 403(10443), pp. 2551–64 [online]. Available at https://doi.org/10.1016/S0140-6736(24)01019-5 (accessed 10 September 2025).

Shorr, A.F., Tabak, Y.P., Killian, A.D., Gupta, V., Liu, L.Z. and Kollef, M.H. (2006) ‘Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database’, Critical Care Medicine, 34(10), pp. 2588–95 [online]. Available at https://doi.org/10.1097/01.CCM.0000239121.09533.09 (accessed 10 September 2025).

Vrijens, F., Hulstaert, F., Van de Sande, S., Devriese, S., Morales, I. and Parmentier, Y. (2010) ‘Hospital-acquired, laboratory-confirmed bloodstream infections: linking national surveillance data to clinical and financial hospital data to estimate increased length of stay and healthcare costs’, Journal of Hospital Infection, 75(3), pp. 158–62 [online]. Available at https://doi.org/10.1016/j.jhin.2009.12.006 (accessed 10 September 2025).

World Health Organization/Food and Agriculture Organization of the United Nations/United Nations Environment Programme/World Organisation for Animal Health (WHO/FAO/UNEP/WOAH) (2023) A One Health Priority Research Agenda for Antimicrobial Resistance. Geneva: WHO [online]. Available at https://www.woah.org/app/uploads/2023/06/one-health-amr-research-prioritisation-launch-v7-2.pdf (accessed 10 September 2025).